2024-515169-33-00招募中2 期
Blomia tropicalis allergen extract. Determination of the vivo histamine equivalent prick test units
Inmunotek S.L.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年10月20日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- The primary efficacy endpoint involves measuring the area (mm2) of the induced wheal on the skin upon applying each of the 3 concentrations of the allergenic extract, as well as those induced by positive (histamine) and negative controls, through the prick test.
研究概览
简要总结
The primary objective is to assess the concentration of Blomia tropicalis allergenic extract that induces a wheal of size equivalent to that produced by a 10 mg/mL histamine dihydrochloride solution.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Female or male aged 18 to 64 years, both included.
- •Subjects who have signed and dated the informed consent form.
- •Subjects must reside in a geographical area where allergic problems caused by Blomia tropicalis are relevant.
- •Positive medical history of inhalant allergy (rhinitis and/or rhinoconjunctivitis and/or asthma) to Blomia tropicalis
- •A positive prick-test (mean wheal diameter ≥ 3 mm) with an extract of the same allergen and/or presence of specific IgE against complete extract or any molecular component to the allergenic source.
- •The area of the wheal obtained with 10 mg/mL histamine dihydrochloride should be ≥ 7 mm², which corresponds to a mean wheal diameter ≥ 3 mm.
- •The area of the wheal obtained with negative control should be < 7 mm², which corresponds to a mean wheal diameter < 3 mm.
- •Women of childbearing age (i.e following menarche and until postmenopause, defined as no menses for 12 months without an alternative medical cause, or non-subject to permanent sterilization methods, such as hysterectomy, bilateral salpingectomy and bilateral oophorectomy) must present a negative urine pregnancy test at the time of enrollment in the trial, as well as a confirmed menstrual period.
- •Women of childbearing age must commit to using a highly effective and adequate contraception method during the trial and up to 72 hours after the end of treatment with the investigational medicinal product. Such methods include combined (estrogen and progestogen containing) hormonal; contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence.
排除标准
- •Subjects outside the age range.
- •Subjects with any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, hypertension, heart disease, etc.).
- •States in which the subject is unable to offer cooperation and severe psychiatric disorders.
- •Pregnant or potentially pregnant women and breastfeeding women.
- •Subjects with known phenol allergy.
- •Subjects who have previously received immunotherapy within the last 5 years for the treatment of asthma or allergic rhinoconjunctivitis induced by allergens that may interfere with Blomia tropicalis extract.
- •Subjects with significant symptoms of rhinoconjunctivitis and/or bronchial asthma in whom discontinuation of systemic antihistamine treatment is contraindicated.
- •Subjects who have previously exhibited a severe adverse reaction during diagnostic skin prick tests.
- •Subjects on treatment with ß-blockers.
- •Use of drugs that could interfere with skin prick test reactions (e.g., antihistamines).
- •Clinically unstable subjects (acute asthma, febrile, etc.).
- •Subjects with active urticaria lesions, severe active dermographism, severe atopic dermatitis, sunburn, eczema, psoriasis lesions in the area where the prick test is performed (risk of false positives).
- •Subjects with active herpes simplex viral infection, or herpes varicella zoster in the area where the prick test is performed.
结局指标
主要结局
The primary efficacy endpoint involves measuring the area (mm2) of the induced wheal on the skin upon applying each of the 3 concentrations of the allergenic extract, as well as those induced by positive (histamine) and negative controls, through the prick test.
The primary efficacy endpoint involves measuring the area (mm2) of the induced wheal on the skin upon applying each of the 3 concentrations of the allergenic extract, as well as those induced by positive (histamine) and negative controls, through the prick test.
次要结局
- Overall rate, seriousness, and ratio of any adverse event (AE) by administration and by subject.
- Assessment of administration site reactions, systemic reactions and any medication administered for the treatment of adverse reaction (AR).
研究者
Miguel Casanovas
Scientific
Inmunotek S.L.
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Determination of Blomia Tropicalis Allergen Extract in Prick Test UnitsAllergic ReactionsAllergic Skin ReactionNCT07195929Inmunotek S.L.30
已完成
2 期
Biological Standardization of Blomia Tropicalis Allergen ExtractAllergy to MitesNCT01597752Laboratorios Leti, S.L.20
已完成
2 期
Efficacy of VALERGENT-BT subcutaneous vaccine in asthmatic adultsAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessBronchial asthmaRPCEC00000026ational Biopreparations Center (BIOCEN)
已完成
2 期
Efficacy of VALERGEN-BT sublingual vaccine in asthmatic adults.AsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000029ational Biopreparations Center (BIOCEN)
已完成
2 期
Evidence of the clinical efficacy of VALERGEN-BT vaccine in asthmaticsAsthmaBronchial asthma.Bronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000033ational Biopreparations Center (BIOCEN)